Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25994013
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 BMJ+Clin+Evid
2015 ; 2015
(ä): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Atrial fibrillation (chronic)
#MMPMID25994013
Lane DA
; Boos CJ
; Lip GY
BMJ Clin Evid
2015[May]; 2015
(ä): ä PMID25994013
show ga
INTRODUCTION: Atrial fibrillation is a supraventricular tachyarrhythmia
characterised by the presence of fast and uncoordinated atrial activation leading
to reduced atrial mechanical function. Risk factors for atrial fibrillation
include increasing age, male sex, co-existing cardiac and thyroid disease,
pyrexial illness, electrolyte imbalance, cancer, and co-existing infection.
METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the
following clinical question: What are the effects of oral medical treatments to
control heart rate in people with chronic (defined as longer than 1 week for this
review) non-valvular atrial fibrillation? We searched: Medline, Embase, The
Cochrane Library, and other important databases up to May 2014 (Clinical Evidence
reviews are updated periodically; please check our website for the most
up-to-date version of this review). We included harms alerts from relevant
organisations such as the US Food and Drug Administration (FDA) and the UK
Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found
four studies that met our inclusion criteria. We performed a GRADE evaluation of
the quality of evidence for interventions. CONCLUSIONS: In this systematic review
we present information relating to the effectiveness and safety of the following
interventions: beta-blockers (rate-limiting, with or without digoxin),
calcium-channel blockers (with or without digoxin), and digoxin.
|Adrenergic beta-Antagonists/*therapeutic use
[MESH]
free
free
free
